HK1201460A1 - Pyrazine kinase inhibitors - Google Patents
Pyrazine kinase inhibitorsInfo
- Publication number
- HK1201460A1 HK1201460A1 HK15102026.7A HK15102026A HK1201460A1 HK 1201460 A1 HK1201460 A1 HK 1201460A1 HK 15102026 A HK15102026 A HK 15102026A HK 1201460 A1 HK1201460 A1 HK 1201460A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- kinase inhibitors
- pyrazine
- pyrazine kinase
- inhibitors
- kinase
- Prior art date
Links
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 title 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
- C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161563466P | 2011-11-23 | 2011-11-23 | |
PCT/US2012/066468 WO2013078466A1 (en) | 2011-11-23 | 2012-11-23 | Pyrazine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1201460A1 true HK1201460A1 (en) | 2015-09-04 |
Family
ID=48427516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15102026.7A HK1201460A1 (en) | 2011-11-23 | 2015-02-28 | Pyrazine kinase inhibitors |
Country Status (18)
Country | Link |
---|---|
US (2) | US9359308B2 (xx) |
EP (1) | EP2782579B1 (xx) |
JP (1) | JP6039683B2 (xx) |
KR (1) | KR102019530B1 (xx) |
CN (1) | CN104066431B (xx) |
AU (1) | AU2012340555B2 (xx) |
BR (1) | BR112014012396B1 (xx) |
CA (2) | CA3094793A1 (xx) |
CL (1) | CL2014001346A1 (xx) |
CO (1) | CO6990735A2 (xx) |
EA (1) | EA026939B1 (xx) |
HK (1) | HK1201460A1 (xx) |
IL (1) | IL232701A (xx) |
IN (1) | IN2014CN04065A (xx) |
MX (1) | MX363551B (xx) |
SG (2) | SG10201601352UA (xx) |
WO (1) | WO2013078466A1 (xx) |
ZA (1) | ZA201403651B (xx) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
ES2546502T3 (es) | 2008-04-16 | 2015-09-24 | Portola Pharmaceuticals, Inc. | 2,6-Diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o JAK quinasas |
MX363551B (es) | 2011-11-23 | 2019-03-27 | Portola Pharmaceuticals Inc Star | Compuestos derivados de pirazina como inhibidores de cinasa. |
US20130310387A1 (en) * | 2012-05-16 | 2013-11-21 | Novartis Ag | Monocyclic Heteroaryl Cycloalkyldiamine Derivatives |
WO2014060371A1 (en) * | 2012-10-19 | 2014-04-24 | F. Hoffmann-La Roche Ag | Inhibitors of syk |
EP3077388A1 (en) | 2013-12-05 | 2016-10-12 | Pharmacyclics, LLC | Inhibitors of bruton's tyrosine kinase |
WO2015138273A1 (en) | 2014-03-13 | 2015-09-17 | Merck Sharp & Dohme Corp. | 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors |
CZ306322B6 (cs) | 2014-12-17 | 2016-11-30 | Univerzita Karlova v Praze, Farmaceutická fakulta v Hradci Králové | Substituovaný 2-(2-fenylhydrazinyl)pyrazin, způsob jeho přípravy, jeho použití a farmaceutický přípravek ho obsahující |
US20180305348A1 (en) * | 2015-06-02 | 2018-10-25 | Pharmacyclics Llc | Inhibitors of brutons tyrosine kinase |
US11708353B2 (en) * | 2018-06-08 | 2023-07-25 | The General Hospital Corporation | Inhibitors of prolyl-tRNA-synthetase |
CN112047899A (zh) * | 2020-10-19 | 2020-12-08 | 成都睿智化学研究有限公司 | 一种合成3-取代氨基苯并[c]异噻唑衍生物的方法 |
WO2023178094A2 (en) * | 2022-03-14 | 2023-09-21 | Purdue Research Foundation | Spleen tyrosine kinase inhibitor, composition, and methods of use |
Family Cites Families (141)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5728536A (en) | 1993-07-29 | 1998-03-17 | St. Jude Children's Research Hospital | Jak kinases and regulation of Cytokine signal transduction |
US5691364A (en) * | 1995-03-10 | 1997-11-25 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
US6004981A (en) | 1996-03-08 | 1999-12-21 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
CA2214685C (en) | 1995-03-10 | 2008-05-20 | Berlex Laboratories, Inc. | Benzamidine derivatives their preparation and their use as anti-coagulants |
US6316635B1 (en) | 1995-06-07 | 2001-11-13 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
AU726522B2 (en) | 1995-09-01 | 2000-11-09 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
US5811428A (en) | 1995-12-18 | 1998-09-22 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
US6696448B2 (en) | 1996-06-05 | 2004-02-24 | Sugen, Inc. | 3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors |
US6008234A (en) | 1996-09-12 | 1999-12-28 | Berlex Laboratories, Inc. | Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants |
PT929547E (pt) | 1996-09-12 | 2003-03-31 | Schering Ag | Derivados da benzamidina substituidos por derivados de aminoacidos ciclicos e de hidroxiacidos ciclicos e seu uso como anticoagulantes |
US6004985A (en) | 1996-10-09 | 1999-12-21 | Berlex Laboratories, Inc. | Thio acid derived monocylic N-heterocyclics as anticoagulants |
US6486185B1 (en) | 1997-05-07 | 2002-11-26 | Sugen, Inc. | 3-heteroarylidene-2-indolinone protein kinase inhibitors |
US6316429B1 (en) | 1997-05-07 | 2001-11-13 | Sugen, Inc. | Bicyclic protein kinase inhibitors |
GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
US6133305A (en) | 1997-09-26 | 2000-10-17 | Sugen, Inc. | 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity |
US6686364B2 (en) | 1997-12-08 | 2004-02-03 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
EP1054004B1 (en) | 1997-12-15 | 2008-07-16 | Astellas Pharma Inc. | Novel pyrimidine-5-carboxamide derivatives |
EP1091739A1 (en) | 1998-06-30 | 2001-04-18 | Parker Hughes Institute | Method for inhibiting c-jun expression using jak-3 inhibitors |
AU5682799A (en) | 1998-08-21 | 2000-03-14 | Parker Hughes Institute | Quinazoline derivatives |
US6262088B1 (en) | 1998-11-19 | 2001-07-17 | Berlex Laboratories, Inc. | Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants |
US6127376A (en) | 1998-12-04 | 2000-10-03 | Berlex Laboratories, Inc. | Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants |
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
US6841567B1 (en) | 1999-02-12 | 2005-01-11 | Cephalon, Inc. | Cyclic substituted fused pyrrolocarbazoles and isoindolones |
GB9904995D0 (en) | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Substituted aza-oxindole derivatives |
US6624171B1 (en) | 1999-03-04 | 2003-09-23 | Smithkline Beecham Corporation | Substituted aza-oxindole derivatives |
US6080747A (en) | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
AU5107900A (en) * | 1999-06-09 | 2000-12-28 | Yamanouchi Pharmaceutical Co., Ltd. | Novel heterocyclic carboxamide derivatives |
AU5108000A (en) * | 1999-06-10 | 2001-01-02 | Yamanouchi Pharmaceutical Co., Ltd. | Novel nitrogen-contaiing heterocyclic derivatives or salts thereof |
GB9918035D0 (en) | 1999-07-30 | 1999-09-29 | Novartis Ag | Organic compounds |
JP2003518023A (ja) | 1999-11-30 | 2003-06-03 | パーカー ヒューズ インスティテュート | トロンビン誘導血小板凝集の阻害剤 |
JP4078074B2 (ja) | 1999-12-10 | 2008-04-23 | ファイザー・プロダクツ・インク | ピロロ[2,3−d]ピリミジン化合物 |
JP2003518123A (ja) | 1999-12-21 | 2003-06-03 | スージェン・インコーポレーテッド | 4−置換7−アザ−インドリン−2−オンおよびその蛋白質キナーゼ阻害剤としての使用 |
US20020065270A1 (en) | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
DE60129926T2 (de) | 2000-01-24 | 2008-06-19 | Genzyme Corp., Cambridge | Inhibitoren des jak/stat-weges und deren verwendung zur behandlung von allgemeiner primärer osteoarthritis |
ATE269860T1 (de) | 2000-01-31 | 2004-07-15 | Pfizer Prod Inc | Pyrimidinylcarboxamiden als inhibitoren der pde4 isoenzyme |
TR200103787T1 (tr) | 2000-02-05 | 2002-10-21 | Vertex Pharmaceuticals Incorporated | Hücre-dışı sinyal ayarlı kinazların(ERK) inhibitörü olarak yararlı pirazol bileşimler |
AU782878B2 (en) | 2000-02-05 | 2005-09-08 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of erk |
GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
US6525051B2 (en) | 2000-03-27 | 2003-02-25 | Schering Aktiengesellschaft | N-heterocyclic derivatives as NOS inhibitors |
US6608048B2 (en) | 2000-03-28 | 2003-08-19 | Wyeth Holdings | Tricyclic protein kinase inhibitors |
AR028261A1 (es) | 2000-03-28 | 2003-04-30 | Wyeth Corp | Inhibidores triciclicos de la proteina quinasa |
WO2001085700A2 (en) | 2000-05-08 | 2001-11-15 | Janssen Pharmaceutica N.V. | Hiv replication inhibiting pyrimidines and triazines |
HUP0301114A3 (en) | 2000-06-26 | 2004-11-29 | Pfizer Prod Inc | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents and pharmaceutical compositions containing them |
GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
WO2002043735A1 (en) | 2000-11-29 | 2002-06-06 | Parker Hughes Institute | Inhibitors of thrombin induced platelet aggregation |
US20020115173A1 (en) | 2000-12-11 | 2002-08-22 | Children's Medical Center Corporation | Short peptides from the 'A-region' of protein kinases which selectively modulate protein kinase activity |
EP1349852A2 (en) | 2000-12-20 | 2003-10-08 | Sugen, Inc. | 4-(hetero)aryl substituted indolinones |
MXPA03005696A (es) | 2000-12-21 | 2003-10-06 | Glaxo Group Ltd | Pirimidinaminas como moduladores de angiogenesis. |
FR2818642B1 (fr) | 2000-12-26 | 2005-07-15 | Hoechst Marion Roussel Inc | Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion |
JP2004528295A (ja) | 2001-01-30 | 2004-09-16 | サイトピア ピーティワイ リミテッド | キナーゼ阻害方法 |
AUPR279101A0 (en) | 2001-01-30 | 2001-02-22 | Cytopia Pty Ltd | Protein kinase signalling |
SE0101675D0 (sv) | 2001-05-11 | 2001-05-11 | Astrazeneca Ab | Novel composition |
PL367130A1 (en) | 2001-05-29 | 2005-02-21 | Schering Aktiengesellschaft | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
JP4541695B2 (ja) | 2001-06-15 | 2010-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼインヒビターとしての5−(2−アミノピリミジン−4−イル)ベンズイソキサゾール |
US6433018B1 (en) | 2001-08-31 | 2002-08-13 | The Research Foundation Of State University Of New York | Method for reducing hypertrophy and ischemia |
WO2003020698A2 (en) | 2001-09-06 | 2003-03-13 | Prochon Biotech Ltd. | Protein tyrosine kinase inhibitors |
CA2459879A1 (en) | 2001-09-10 | 2003-03-20 | Sugen, Inc. | 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors |
WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
EP1434774A1 (en) | 2001-10-10 | 2004-07-07 | Sugen, Inc. | 3-(4-substituted heterocyclyl)-pyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors |
GT200200234A (es) | 2001-12-06 | 2003-06-27 | Compuestos cristalinos novedosos | |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
US6998391B2 (en) | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
CA2476281A1 (en) | 2002-02-08 | 2003-08-14 | Smithkline Beecham Corporation | Pyrimidine compounds |
US7338959B2 (en) | 2002-03-01 | 2008-03-04 | Smithkline Beecham Corporation | Diamino-pyrimidines and their use as angiogenesis inhibitors |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
AU2003231231A1 (en) | 2002-05-06 | 2003-11-11 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
CA2485429A1 (en) | 2002-05-06 | 2004-07-15 | Vertex Pharmaceuticals Incorporated | Thiadiazoles or oxadiazoles and their use as inhibitors of jak protein kinase |
CA2487679A1 (en) | 2002-05-30 | 2003-12-11 | Vertex Pharmaceuticals Incorporated | Inhibitors of jak and cdk2 protein kinases |
CN1688553A (zh) | 2002-06-17 | 2005-10-26 | 史密丝克莱恩比彻姆公司 | 化学方法 |
JP4529685B2 (ja) | 2002-06-28 | 2010-08-25 | アステラス製薬株式会社 | ジアミノピリミジンカルボキサミド誘導体 |
CN1678321A (zh) | 2002-07-29 | 2005-10-05 | 里格尔药品股份有限公司 | 用2,4-嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法 |
BR0313397A (pt) | 2002-08-14 | 2005-06-28 | Vertex Pharmaceuticals Incorpo | Inibidores de proteina cinase e usos destes |
CA2506772A1 (en) | 2002-11-01 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of jak and other protein kinases |
CA2506773A1 (en) | 2002-11-04 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Heteroaryl-pyramidine derivatives as jak inhibitors |
CA2507406A1 (en) | 2002-11-05 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of jak and other protein kinases |
TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
RU2309147C9 (ru) | 2002-11-21 | 2008-03-20 | Пфайзер Продактс Инк. | Производные 3-аминопиперидина и способы их получения |
BR0316487A (pt) | 2002-11-26 | 2005-10-11 | Pfizer Prod Inc | Método todo de tratamento da rejeição de transplantes |
DE60326646D1 (de) | 2002-12-18 | 2009-04-23 | Vertex Pharma | Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen |
DE602004021472D1 (en) | 2003-02-20 | 2009-07-23 | Smithkline Beecham Corp | Pyrimiidinverbindungen |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
EP1615906A1 (en) | 2003-04-03 | 2006-01-18 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
EP1651599A4 (en) | 2003-07-24 | 2008-09-24 | Merck & Co Inc | TYROSINE KINASE INHIBITORS |
US7122542B2 (en) | 2003-07-30 | 2006-10-17 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
MXPA06001762A (es) | 2003-08-14 | 2006-05-12 | Pfizer | Derivados de piperazina. |
JP4607879B2 (ja) | 2003-08-15 | 2011-01-05 | ノバルティス アーゲー | 新生物疾患、炎症および免疫障害の処置に有用な2,4−ピリミジンジアミン |
TWI339206B (en) | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
GB0321710D0 (en) | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
WO2005033086A1 (en) | 2003-09-30 | 2005-04-14 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
ES2295924T3 (es) | 2003-10-03 | 2008-04-16 | Pfizer, Inc. | Derivados de tropano imidazopirina sustituidos con actividad antagonista de los receptores ccr5 para el tratamiento de vih y de la inflamacion. |
DE10349423A1 (de) | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
MXPA06007640A (es) | 2004-01-12 | 2007-04-17 | Cytopia Res Pty Ltd | Inhibidores de quinasa selectivos. |
CA2560454C (en) | 2004-03-30 | 2013-05-21 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of jak and other protein kinases |
GB0407723D0 (en) | 2004-04-05 | 2004-05-12 | Novartis Ag | Organic compounds |
JP4876915B2 (ja) | 2004-06-14 | 2012-02-15 | 日本電気株式会社 | フィルム外装電気デバイス |
WO2006027377A1 (en) | 2004-09-10 | 2006-03-16 | Altana Pharma Ag | Ciclesonide and syk inhibitor combination and methods of use thereof |
EP1791538A1 (en) | 2004-09-10 | 2007-06-06 | Altana Pharma AG | Roflumilast and syk inhibitor combination and methods of use thereof |
DK1814878T3 (da) | 2004-11-24 | 2012-05-07 | Rigel Pharmaceuticals Inc | Spiro-2, 4-pyrimidindiamin-forbindelser og anvendelser deraf |
DK1856135T3 (da) | 2005-01-19 | 2010-04-12 | Rigel Pharmaceuticals Inc | Prodrugs af 2,4-pyrimidindiamin-forbindelser og deres anvendelser |
US20060270694A1 (en) | 2005-05-03 | 2006-11-30 | Rigel Pharmaceuticals, Inc. | JAK kinase inhibitors and their uses |
JP2009511528A (ja) | 2005-10-13 | 2009-03-19 | グラクソ グループ リミテッド | Syk阻害物質としてのピロロピリミジン誘導体群 |
WO2007046112A1 (en) | 2005-10-19 | 2007-04-26 | Suven Life Sciences Inc. | Arylthioether tryptamine derivatives as functional 5-ht6 ligands |
CA2633035C (en) | 2005-12-15 | 2016-05-10 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and their uses |
NL2000323C2 (nl) | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine-derivaten. |
GB0526246D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
EP2004632B1 (en) | 2006-03-30 | 2014-03-12 | Janssen R&D Ireland | Hiv inhibiting 5-amido substituted pyrimidines |
US8258129B2 (en) | 2006-07-06 | 2012-09-04 | Boehringer Ingelheim International Gmbh | 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments |
US20100010025A1 (en) | 2006-07-21 | 2010-01-14 | Norvartis Ag | Pyrimidine Derivatives |
WO2008024963A1 (en) | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Benzene, pyridine, and pyridazine derivatives |
EP2222647B1 (en) | 2006-10-23 | 2015-08-05 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
US20080139531A1 (en) | 2006-12-04 | 2008-06-12 | Alcon Manufacturing Ltd. | Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair |
AU2007341228B2 (en) | 2006-12-29 | 2013-04-18 | Janssen Sciences Ireland Uc | HIV inhibiting 5,6-substituted pyrimidines |
RU2009140319A (ru) | 2007-04-02 | 2011-05-10 | Палау Фарма С.А. (Es) | Производные пирролпиримидина |
JP2010526048A (ja) | 2007-05-04 | 2010-07-29 | アストラゼネカ アクチボラグ | アミノ−チアゾリル−ピリミジン誘導体、および癌の治療のための該誘導体の使用 |
EP2157090A4 (en) | 2007-06-21 | 2011-09-07 | Taisho Pharmaceutical Co Ltd | PYRAZINAMIDVERBINDUNG |
MX2010002336A (es) | 2007-08-28 | 2010-03-25 | Irm Llc | Derivados de 2-bifenil-amino-4-amino-pirimidina como inhibidores de cinasa. |
US20100292447A1 (en) | 2007-10-12 | 2010-11-18 | Merck Patent Gesellschaft | Method and agent for refolding proteins |
US20090270418A1 (en) | 2008-01-09 | 2009-10-29 | Marianne Sloss | Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith |
US20090196973A1 (en) | 2008-02-01 | 2009-08-06 | Rich Products Corporation | Foam Compositions |
CA2723205C (en) | 2008-04-16 | 2017-03-14 | Portola Pharmaceuticals, Inc. | 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinase inhibitors |
ES2546502T3 (es) | 2008-04-16 | 2015-09-24 | Portola Pharmaceuticals, Inc. | 2,6-Diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o JAK quinasas |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
KR20170051521A (ko) | 2008-04-16 | 2017-05-11 | 포톨라 파마슈티컬스, 인코포레이티드 | syk 또는 JAK 키나제 억제제로서의 2,6-디아미노-피리미딘-5-일-카르복스아미드 |
AU2009238590A1 (en) | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
EP2331507A2 (en) * | 2008-09-18 | 2011-06-15 | Astellas Pharma Inc. | Heterocyclic carboxamide compounds |
US20110230467A1 (en) | 2008-11-21 | 2011-09-22 | Astellas Pharma Inc. | 4,6-diaminonicotinamide compound |
BRPI0920966B1 (pt) | 2008-11-28 | 2022-03-03 | Kowa Company Ltd | Derivado de piridina-3-carboxiamida, seu uso, inibidor de jak3 e composição farmacêutica |
EP2376481B1 (en) | 2009-01-13 | 2013-08-07 | Glaxo Group Limited | Pyrimidinecarboxamide derivatives as inhibitors of syk kinase |
TW201040162A (en) | 2009-05-06 | 2010-11-16 | Portola Pharm Inc | Inhibitors of JAK |
PT2428508E (pt) * | 2009-05-08 | 2016-02-29 | Kotobuki Pharmaceutical Co Ltd | Composto diamino-carboxamida heterocíclico |
WO2012045010A1 (en) | 2010-09-30 | 2012-04-05 | Portola Pharmaceuticals, Inc. | Combinations of 4-(3-(2h-1,2,3-triazo-2-yl) phenylamino)-2-((1r,2s)-2-aminocyclohexylamino) pyrimidine-5-carboxamide and fludarabine |
US20130244963A1 (en) | 2010-09-30 | 2013-09-19 | Portola Pharmaceuticals, Inc. | Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide |
JP2014005206A (ja) | 2010-10-22 | 2014-01-16 | Astellas Pharma Inc | アリールアミノヘテロ環カルボキサミド化合物 |
WO2012061415A1 (en) | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Oxypyrimidines as syk modulators |
EP2975027A1 (en) | 2010-11-01 | 2016-01-20 | Portola Pharmaceuticals, Inc. | Nicotinamides as jak kinase modulators |
WO2013078468A1 (en) | 2011-11-23 | 2013-05-30 | Portola Pharmaceuticals, Inc. | Selective kinase inhibitors |
MX363551B (es) | 2011-11-23 | 2019-03-27 | Portola Pharmaceuticals Inc Star | Compuestos derivados de pirazina como inhibidores de cinasa. |
-
2012
- 2012-11-23 MX MX2014006242A patent/MX363551B/es unknown
- 2012-11-23 CA CA3094793A patent/CA3094793A1/en not_active Abandoned
- 2012-11-23 SG SG10201601352UA patent/SG10201601352UA/en unknown
- 2012-11-23 CA CA2856301A patent/CA2856301C/en not_active Expired - Fee Related
- 2012-11-23 US US14/360,178 patent/US9359308B2/en active Active
- 2012-11-23 IN IN4065CHN2014 patent/IN2014CN04065A/en unknown
- 2012-11-23 AU AU2012340555A patent/AU2012340555B2/en not_active Ceased
- 2012-11-23 JP JP2014543599A patent/JP6039683B2/ja active Active
- 2012-11-23 CN CN201280067711.XA patent/CN104066431B/zh active Active
- 2012-11-23 KR KR1020147016958A patent/KR102019530B1/ko active IP Right Grant
- 2012-11-23 US US13/684,462 patent/US8877760B2/en active Active
- 2012-11-23 EP EP12852197.8A patent/EP2782579B1/en active Active
- 2012-11-23 WO PCT/US2012/066468 patent/WO2013078466A1/en active Application Filing
- 2012-11-23 SG SG11201402570QA patent/SG11201402570QA/en unknown
- 2012-11-23 EA EA201491013A patent/EA026939B1/ru not_active IP Right Cessation
- 2012-11-23 BR BR112014012396-9A patent/BR112014012396B1/pt not_active IP Right Cessation
-
2014
- 2014-05-19 IL IL232701A patent/IL232701A/en active IP Right Grant
- 2014-05-20 ZA ZA2014/03651A patent/ZA201403651B/en unknown
- 2014-05-22 CL CL2014001346A patent/CL2014001346A1/es unknown
- 2014-06-24 CO CO14135724A patent/CO6990735A2/es unknown
-
2015
- 2015-02-28 HK HK15102026.7A patent/HK1201460A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1222647A1 (zh) | 激酶抑制劑 | |
HK1210775A1 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
PL2710007T3 (pl) | Inhibitory kinazy | |
HK1208442A1 (en) | Substituted pyrrolopyrimidinylamino-benzothiazolones as mknk kinase inhibitors mknk | |
HK1200451A1 (zh) | 蛋白激酶抑制劑 | |
PT2710005T (pt) | Inibidores de tirosina-quinase | |
IL228103A0 (en) | Amino-quinolines as kinase inhibitors | |
EP2694517A4 (en) | PROTEIN KINASE INHIBITORS | |
HK1201460A1 (en) | Pyrazine kinase inhibitors | |
EP2782580A4 (en) | SELECTIVE INHIBITORS OF KINASES | |
IL229028A0 (en) | Kinase inhibitors | |
EP2685992A4 (en) | AMINO-QUINOLINES AS KINASE INHIBITORS | |
HK1199873A1 (en) | Kinase inhibitors | |
IL232234A0 (en) | Inhibitors of aminopyrimidine kinase | |
IL228928A0 (en) | Aminopyrimidine kinase inhibitors | |
SG11201500973WA (en) | Amino-quinolines as kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20231121 |